Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2017

View Archived Issues

Flx Bio names first immuno-oncology clinical candidate

DS-1205b shows promising in vitro and in vivo antitumoral activity

AVROBIO announces new program in Pompe disease

Transgene announces launch of Invir.IO platform

ODM-208 shows promise for the treatment of castration-resistant prostate cancer

CPL-410-005, a potent E1 inhibitor, shows promise for the treatment of solid tumors

Arbutus Biopharma provides updated data from phase II study of ARB-1467

First patient recruited in phase III study of Athenex's KX-01 for actinic keratosis

Preliminary topline data from phase III trial of Sinovac's varicella vaccine reported

Bill & Melinda Gates Foundation and Anacor patent boron-containing small molecules

Shenzhen Targetrx Biotechnology divulges novel ALK inhibitors

ATM kinase inhibitors presented by AstraZeneca

Shanghai Institute of Organic Chemistry discloses IDO-1 inhibitors

The Brigham and Women's Hospital identifies SMOC2 inhibitors

Allergan reveals new results from CENTAUR study of cenicriviroc in NASH

Opdivo approved for gastric cancer in Japan

Hyaluronan predictive of improvement in survival outcomes in PEGPH-20 trial

Glenmark to return certain crofelemer rights to Napo in 141 countries

A novel ITPR1 gene mutation found for refractory epilepsy

ARGX-113 begins phase II study for pemphigus vulgaris, designated orphan drug for myasthenia gravis

EC approves Symtuza for HIV-1 in adolescents and adults, NDA filed in U.S.

Akari Therapeutics to advance coversin into phase III studies in PNH

Asahi Kasei obtains license to Preob from Bone Therapeutics

U.S. and E.U. orphan drug designation granted to Vivet's gene therapy VTX-801 for Wilson's disease

EpiVax launches precision immunotherapy venture

Selexis and OSE sign commercial license agreements to support OSE-172 and OSE-703 programs

AbbVie, BMS enter agreement to test ABBV-399 with Opdivo in NSCLC

ProQR reports promising topline data from phase Ib study of QR-010 in cystic fibrosis

ImmuPharma offers update on Lupuzor program

Dova Pharmaceuticals submits NDA in U.S. for avatrombopag

European Commission approves Vimpat for pediatric use

Keytruda and companion diagnostic approved in U.S. for advanced gastric cancer

Mallinckrodt completes acquisition of InfaCare Pharmaceutical

Janssen Biotech receives complete response letter for sirukumab BLA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...